Christopher Ruland

Title: Christopher Ruland: Innovator in Cancer Treatment

Introduction

Christopher Ruland is a notable inventor based in Annapolis, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patenting efforts. His work focuses on developing pharmaceutical compositions that can aid in the treatment of various neoplastic diseases.

Latest Patents

Ruland holds a patent for "Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer." This invention provides pharmaceutical compositions that include derivatives of NDGA, such as M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib. These compositions are designed to inhibit and treat neoplastic diseases, including liver cancer, colon cancer, breast cancer, brain cancers, and ovarian cancers. The patent highlights the potential of combining NDGA derivatives with sorafenib and additional therapeutic agents for enhanced treatment efficacy.

Career Highlights

Christopher Ruland is affiliated with Johns Hopkins University, where he continues to engage in groundbreaking research. His work has positioned him as a key figure in the development of innovative cancer therapies. Ruland's dedication to improving patient outcomes through scientific advancements is evident in his research endeavors.

Collaborations

Ruland has collaborated with esteemed colleagues, including Yu-Chuan Liang and Ru Chih Huang. These partnerships have fostered a collaborative environment that enhances the research and development of effective cancer treatments.

Conclusion

Christopher Ruland's contributions to cancer treatment through his patented inventions exemplify the impact of innovative research in medicine. His work at Johns Hopkins University and collaborations with fellow researchers underscore the importance of teamwork in advancing healthcare solutions.